Grard, Marion
Idjellidaine, Mohamed
Arbabian, Atousa
Chatelain, Camille
Berland, Laurine
Combredet, Chantal
Dutoit, Soizic
Deshayes, Sophie
Dehame, Virginie
Labarrière, Nathalie
Fradin, Delphine
Boisgerault, Nicolas
Blanquart, Christophe
Tangy, Frédéric
Fonteneau, Jean-François
Funding for this research was provided by:
La Ligue Régionale Grand Ouest contre le Cancer (CD16, CD22, CD44, CD49, CD72, CD79 and CD85)
association ARSMESO44 (meso44)
Fondation ARC (PJA 20191209661)
Agence Nationale de la Recherche (ANR-16-CE18-0016)
Agence Nationale pour la Recherche, France (LabEX IGO, ANR-11-LABX-0016-01)
Article History
Received: 12 September 2022
Accepted: 26 June 2023
First Online: 19 July 2023
Declarations
:
: FT and JFF are authors of patents on MV. FT owns equity in Oncovita, an oncolytic virotherapy company.